Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics
link https://doi.org/10.1016/j.diabres.2005.07.009account_box Olmos, PRaccount_box Hodgson, MIaccount_box Maiz, Aaccount_box Manrique, Maccount_box De Valdes, MDaccount_box Foncea, Raccount_box Acosta, AMaccount_box Emmerich, MVaccount_box Velasco, S
Comparte este registro
Background: After a study of ICA prevalence among relatives of Type-1 diabetics (DMI) in Santiago, Chile, parents of those who tested positive asked us to go on forward with an intervention study.
Registro Sencillo
Registro Completo
| Autor | Olmos, PR Hodgson, MI Maiz, A Manrique, M De Valdes, MD Foncea, R Acosta, AM Emmerich, MV Velasco, S |
| Título | Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics |
| Revista | DIABETES RESEARCH AND CLINICAL PRACTICE |
| ISSN | 0168-8227 |
| Volumen | 71 |
| Número de publicación | 3 |
| Página inicio | 320 |
| Página final | 333 |
| Fecha de publicación | 2006 |
| Resumen | Background: After a study of ICA prevalence among relatives of Type-1 diabetics (DMI) in Santiago, Chile, parents of those who tested positive asked us to go on forward with an intervention study. Methods: We had screened 1021 relatives, of which 30 had shown ICA >= 20 JDF units (2.9%). Among the 26/30 who participated in the intervention study, the baseline screening showed normal glucose tolerance in all, and the first-phase insulin response (FPIR) was normal in 24/26 individuals, which were randomized into Nicotinamide (n = 12; oral Nicotinamide, 1200 mg m(-2) day(-1)) and Placebo (n = 12) groups. The FPIRs and ICAs were monitored yearly. Compliance was monitored by urine Nicotinamide. Results: The 1.5, 3.0 and 5-year life-table estimates of keeping the FPIR >= 10th centile were, for Nicotinamide group 100% in all time points, and for Placebo these were 90.0% (c.i. = 100-71.4), 72.0% (c.i. = 100-37.1) and 0.0% (c.i. = 0.0-0.0) (p = 0.0091). The 5-year life-table estimates of remaining diabetes-free were 100% for Nicotinamide and 62.5% for Placebo (p = 0.0483). No adverse effects were observed. Conclusions: Oral Nicotinamide protected beta-cell function and prevented clinical disease in ICA-positive first-degree relatives of type-1 diabetes. (c) 2005 Elsevier Ireland Ltd. All rights reserved. |
| Derechos | acceso restringido |
| DOI | 10.1016/j.diabres.2005.07.009 |
| Editorial | ELSEVIER IRELAND LTD |
| Enlace | |
| Id de publicación en Pubmed | MEDLINE:16233932 |
| Id de publicación en WoS | WOS:000236292500014 |
| Paginación | 14 páginas |
| Palabra clave | type-1 diabetes mellitus nicotinamide prevention ISLET-CELL ANTIBODIES INTERVENTION TRIAL ENDIT INTRAVENOUS GLUCOSE FOLLOW-UP T-CELLS CHILDREN MELLITUS PHASE PROGRESSION PREDICTION |
| Tema ODS | 03 Good Health and Well-being |
| Tema ODS español | 03 Salud y bienestar |
| Tipo de documento | artículo |